Dermisonics, Inc.
DMSI
Other OTC0.00
USD
- -
- -
Dermisonics, Inc.
DMSI
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Dermisonics, Inc. is a development-stage biopharmaceutical and medical device company specializing in the manufacture and commercialization of ultrasonic transdermal drug-delivery technologies and equipment. Its core products include the U-Strip, an active transdermal patch system integrating microelectronics and ultrasonic technology designed to enable needle-free, efficient delivery of heavy molecular drugs, including insulin, through the skin. The company also develops ultrasonic-assisted drug delivery devices aimed at enhancing the penetration of various pharmaceutical and cosmetic products. Founded in 2000 and headquartered in Irvine, California, Dermisonics primarily operates in the healthcare equipment and medical devices industry within the United States. The company focuses on the development, testing, and commercialization of its transdermal patch technology to facilitate needle-free drug delivery for large molecular drugs that cannot effectively penetrate the skin through traditional transdermal methods. Recent developments include leveraging its ultrasonic drug delivery expertise to expand into cosmetic applications with devices like the U-Wand, a handheld ultrasound device intended for cosmetic product delivery through enhanced skin penetration. This marks an entry into new consumer product markets beyond pharmaceuticals. Dermisonics operates primarily in the US healthcare sector, targeting pharmaceutical companies, biopharmaceutical developers, and cosmetics manufacturers as its customer base. It remains focused on advancing its proprietary drug delivery platform for both medical and cosmetic uses. The company has not reported significant revenue but continues strategic development and potential commercial partnerships to advance its novel transdermal delivery technologies. Dermisonics was formerly known as Second Stage Ventures, Inc. before changing its name in 2004. Its headquarters are located at 2 Park Plaza, Suite 450, Irvine, California. Recent strategic shifts include expanding these ultrasonic delivery applications into wider markets and ongoing development and commercialization efforts of its transdermal patch technology.